公开(公告)号：US11981658B2

公开(公告)日：2024-05-14

申请号：US17822450

申请日：2022-08-26

申请人： YUHAN CORPORATION ,  JANSSEN BIOTECH, INC.

发明人： Byoungmoon Lee ,  Hyunjoo Lee ,  Gyu Jin Lee ,  Su Bin Choi ,  Sol Park ,  Heejun Kim ,  Misong Kim ,  Young Ae Yoon ,  Kwan Hoon Hyun ,  Tae Kyun Kim ,  Jae Young Sim ,  Marian C. Bryan ,  Scott Kuduk ,  James Campbell Robertson

IPC分类号： C07D401/14

CPC分类号： C07D401/14

摘要： Provided are aminopyridine compounds and pharmaceutically acceptable compositions thereof which exhibit inhibition activity against certain mutated forms of EGFR.

公开(公告)号：US11091479B2

公开(公告)日：2021-08-17

申请号：US16712673

申请日：2019-12-12

申请人： YUHAN CORPORATION

发明人： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Dong Hoon Kim ,  Su Bin Choi ,  Sol Park ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha

IPC分类号： C07D471/04 ,  C07D519/00

摘要： The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US10562865B2

公开(公告)日：2020-02-18

申请号：US16359984

申请日：2019-03-20

申请人： YUHAN CORPORATION

发明人： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Su Bin Choi ,  Dong Hoon Kim ,  Sol Park ,  Eun Hye Jung ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha

IPC分类号： C07D401/04 ,  C07D401/14 ,  C07D249/12 ,  C07D403/10 ,  C07D403/14 ,  C07D405/10 ,  C07D409/10 ,  C07D413/10 ,  C07D417/10 ,  C07D417/14 ,  C07D249/08 ,  C07D403/04 ,  C07D417/04 ,  C07D407/14 ,  C07D401/10 ,  C07D405/14 ,  C07D413/14

摘要： The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US11492335B2

公开(公告)日：2022-11-08

申请号：US17104557

申请日：2020-11-25

申请人： YUHAN CORPORATION

发明人： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Su Bin Choi ,  Dong Hoon Kim ,  Sol Park ,  Eun Hye Jung ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha

IPC分类号： C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D409/10 ,  C07D413/14 ,  C07D417/04 ,  C07D417/14 ,  C07D249/08 ,  C07D401/04 ,  C07D405/10 ,  C07D407/14 ,  C07D401/10 ,  C07D403/10 ,  C07D405/14 ,  C07D413/10 ,  C07D417/10 ,  C07D249/12

摘要： The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US11780830B2

公开(公告)日：2023-10-10

申请号：US17208887

申请日：2021-03-22

申请人： YUHAN CORPORATION

发明人： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Su Bin Choi ,  Sol Park ,  Dong Hoon Kim ,  So Young Kim ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha ,  Eui Chui Lee

IPC分类号： C07D409/04 ,  C07D409/14 ,  C07D498/04 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14

CPC分类号： C07D409/04 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

摘要： The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g. for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US11168073B2

公开(公告)日：2021-11-09

申请号：US16712660

申请日：2019-12-12

申请人： YUHAN CORPORATION

发明人： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Eui Chul Lee ,  Sol Park ,  Hyok Jun Cho ,  Cheol Hee Lim ,  So Young Kim ,  Hyun Ho Choi ,  Da Na Jeong ,  Na Yeon Yang ,  Na Ry Ha

IPC分类号： C07D403/10 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/10 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/14

摘要： The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US11820769B2

公开(公告)日：2023-11-21

申请号：US17368712

申请日：2021-07-06

申请人： YUHAN CORPORATION

发明人： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Dong Hoon Kim ,  Su Bin Choi ,  Sol Park ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha

IPC分类号： C07D471/04 ,  C07D519/00

CPC分类号： C07D471/04 ,  C07D519/00

摘要： The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US11713308B2

公开(公告)日：2023-08-01

申请号：US17368738

申请日：2021-07-06

申请人： YUHAN CORPORATION

发明人： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Eui Chul Lee ,  Sol Park ,  Hyok Jun Cho ,  Cheol Hee Lim ,  So Young Kim ,  Hyun Ho Choi ,  Da Na Jeong ,  Na Yeon Yang ,  Na Ry Ha

IPC分类号： C07D403/10 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/10 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/14

CPC分类号： C07D403/10 ,  C07D249/12 ,  C07D401/04 ,  C07D401/10 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/10 ,  C07D405/14 ,  C07D409/06 ,  C07D409/14 ,  C07D413/14

摘要： The present technology provides 3,3-difluoroallylamines or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The 3,3-difluoroallylamines or their pharmaceutically acceptable salts exhibit potent inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US10995086B2

公开(公告)日：2021-05-04

申请号：US16359985

申请日：2019-03-20

申请人： YUHAN CORPORATION

发明人： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Su Bin Choi ,  Sol Park ,  Dong Hoon Kim ,  So Young Kim ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha ,  Eui Chul Lee

IPC分类号： C07D409/06 ,  C07D409/04 ,  C07D409/14 ,  C07D498/04 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14

摘要： The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US10899719B2

公开(公告)日：2021-01-26

申请号：US16721020

申请日：2019-12-19

申请人： YUHAN CORPORATION

发明人： Tae Dong Han ,  Hee Jae Tak ,  Eun Kyung Kim ,  Su Bin Choi ,  Dong Hoon Kim ,  Sol Park ,  Eun Hye Jung ,  Hyun Ho Choi ,  Tae Wang Kim ,  Mi Kyeong Ju ,  Na Ry Ha

IPC分类号： C07D403/04 ,  C07D249/08 ,  C07D401/04 ,  C07D417/04 ,  C07D409/10 ,  C07D405/10 ,  C07D407/14 ,  C07D401/10 ,  C07D403/10 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D413/10 ,  C07D417/10 ,  C07D249/12 ,  C07D403/14

摘要： The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).